Jean-Pierre Sommadossi

This profile gathers the share dealings of Jean-Pierre Sommadossi across 3 companies, led by Atea Pharmaceuticals, Inc., Idenix Pharmaceuticals Inc and Kezar Life Sciences, Inc. The record holds 17 filings, for trades running from 9 May 2006 to 3 February 2026.

Both buying and selling appear: 1 purchase worth €71k, against 5 sales worth €417k. The net balance comes to €346k on the selling side. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 3 share grants and 4 option exercises.

On 3 February 2026 came the latest disclosure, a share grant for €376k in Atea Pharmaceuticals, Inc. The clock since the last published purchase (11 May 2006) now reads 7,470 days. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.